Teva Pharmaceuticals
TEVA
421 hedge funds and large institutions have $5.04B invested in Teva Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 130 increasing their positions, 140 reducing their positions, and 44 closing their positions.
12% more capital invested
Capital invested by funds: $4.51B → $5.04B (+$531M)
9% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 44
1% more call options, than puts
Call options by funds: $334M | Put options by funds: $330M
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
0.23% less ownership
Funds ownership: 50.46% → 50.23% (-0.23%)
7% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 140
2% less funds holding
Funds holding: 430 → 421 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$98M |
| 2 |
BCP
BSN Capital Partners
London,
United Kingdom
|
+$52.4M |
| 3 |
IAM
Ion Asset Management
Herzliya,
Israel
|
+$45.4M |
| 4 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
+$30.4M |
| 5 |
GAM
Goldentree Asset Management
New York
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$69.5M |
| 2 |
MVP
Miller Value Partners
Sarasota,
Florida
|
-$35.8M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$20.9M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$17.9M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$17M |
TEVA Hedge Fund Activity: Q4 2022 in Review
421 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2022, worth a combined $5.04B — up 12% from $4.51B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new TEVA positions and 44 closed out — a net gain of 4 holders — while 130 added to existing stakes and 140 trimmed.
The largest buyer was Capital World Investors, adding an estimated $98M. The largest seller was Abrams Capital Management, cutting an estimated $69.5M.
- 421 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2022, down from 430 in Q3 2022.
- Funds reported $5.04B of Teva Pharmaceuticals stock for Q4 2022, up 12% quarter-over-quarter.
- 48 funds opened new Teva Pharmaceuticals positions in Q4 2022 and 44 closed out, a net change of +4 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2022 was Capital World Investors, an estimated $98M added.
- The largest Teva Pharmaceuticals seller in Q4 2022 was Abrams Capital Management, an estimated $69.5M sold.
Based on aggregated 13F filings for Q4 2022.